Inebilizumab
Sign in to saveInebilizumab, sold under the brand name Uplizna, is a medication used for the treatment of neuromyelitis optica spectrum disorder, immunoglobulin G4-related disease, and generalized myasthenia gravis. Inebilizumab is a humanized monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody).
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~5 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- History
- Society and culture
- Legal status
- Names
- References
- Further reading
- External links
Inebilizumab, sold under the brand name Uplizna, is a medication used for the treatment of neuromyelitis optica spectrum disorder, immunoglobulin G4-related disease, and generalized myasthenia gravis. Inebilizumab is a humanized monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody).
The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.
Excerpted from Wikipedia’s “Inebilizumab” article, available under the CC BY-SA 4.0 licence.